News Focus
News Focus
icon url

DewDiligence

03/19/22 1:37 PM

#241737 RE: DewDiligence #239626

FDA approves BMY’s Opdualag—a_co-formulated_FDC_of Opdivo and anti-LAG-3 relatlimab—in first-line melanoma:

https://finance.yahoo.com/news/u-food-drug-administration-approves-222900124.html

The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232).

In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity.

My abbreviated take:
https://twitter.com/DewDiligence/status/1395141087413538822